DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient

Information source: Rigshospitalet, Denmark
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Disease; Ischemic Heart Disease; Percutaneous Coronary Intervention; ST-elevation Myocardial Infarction; Thrombocytic Inhibition

Intervention: Upright position (Other)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Rigshospitalet, Denmark

Official(s) and/or principal investigator(s):
Jacob Antonsen, Medical Doctor, Principal Investigator, Affiliation: Rigshospitalet, Denmark

Summary

The purpose of the study is to clarify wether body posture during ingestion of 60mg Efient, a thrombocytic inhibitor, has influence on the time to thrombocytic inhibition. The study aims to mimic the treatment Danish patients receive when admitted to the hospital with a ST-elevation myocardial infarction since these patients are refereed to acute Percutaneous Coronary Intervention (PCI) necessitating fast and efficient thrombocytic inhibition. Current guidelines recommend the administration of Efient right before the PCI procedure, while the patient is lying down, either in the ambulance or in the operating room. We, the investigators, believe that this is suboptimal for the patient, since any sort of prolonged inhibition time will possibly worsen the patients prognosis and make the patient more prone to later clotting issues. Our hypothesis is that by making the patients ingest the tablets in a 90 degrees upright position and making them sit up for 2 minutes after ingestion, the effect of the pills will commence faster than if taken in a supine position. This will possibly lead to faster inhibition of the thrombocytes, which we believe will lead to a lower incidence of clotting issues during and after the procedure.

Clinical Details

Official title: Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change in Inhibition of ADP-receptors on thrombocytes

Detailed description: The study will be divided into two sessions: first session will be the control arm- ingestion of Efient in supine position. 14 days later, the same test-persons will be doing the intervention- ingestion of Efient sitting upright for 2 minutes. Besides this, the second session will be exactly the same as the control arm.

Eligibility

Minimum age: 20 Years. Maximum age: 30 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- 20-30 years of age

- Healthy

- Male

- Ability to give informed consent

- Non-Smoker

Exclusion Criteria:

- Known with reflux or dysphagia

- Ingestion of medicine, beside Paracetamol <14 prior to the trial

- Hematological diseases

- Diabetes

- Known kidney disease

- Known liver disease

- Recent trauma

- Scheduled operation within 7 days after the trial

- Former apoplexia

- Known gastro-intestinal disease

- Weight <60 kg

Locations and Contacts

Nordsjællands Hospital, Hillerød 2100, Denmark
Additional Information

Starting date: February 2011
Last updated: October 23, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017